Navamedic reports 2.2% revenue growth in second quarter

Navamedic ASA reported a modest 2.2% increase in revenue for the second quarter of 2026, reaching NOK 140.3 million. The Norway-based healthcare products company saw an improvement in its adjusted EBITDA margin, which rose to 11.3% from 7.4% in the same period last year. Gross margin for the quarter stood at 38.4%.

The company's Prescription Drugs business area drove growth in the quarter, including contributions from the Addiction portfolio acquired in July 2025. However, the Consumer Health segment experienced a decline in revenue due to heightened competition, particularly affecting the Modifast product. The EBITDA margin was negatively impacted by extraordinary costs related to a CEO change and inventory write-offs during the period.

Navamedic anticipates stable revenue for 2026, similar to 2025 levels. The company expects improved gross margins for the year due to a more favorable product mix. Additionally, EBITDA is projected to improve compared to 2025.